 |
|
|
|
|
06.45– 19.30 |
Registration open |
|
|
| |
|
|
|
07.15 – 08.45 |
Satellite Symposium
Impacting Bone Disease via the
RANK/RANKL/OPG System
Supported by AMGEN Chair: J.-J. Body (Brussels,
Belgium)
|
|
Athena Theatre
|
| |
|
The role of the RANK/RANKL/OPG system in bone remodeling
and resorption |
|
T. J. Chambers (London, UK) |
| |
|
Osteoporosis and the RANK/RANKL/OPG system: considerations
for therapy |
|
L. C. Hofbauer (Marburg, Germany)
|
| |
|
Future directions in the treatment of cancer-related
bone disease: targeting RANKL |
|
J.-J. Body (Brussels, Belgium) |
| |
|
|
|
|
08.00 – 09.00 |
|
Posters |
|
Hall Agora 2 |
| |
|
|
|
|
09.00 – 10.00
|
Symposium 1
Bone Formation Chair: S. Roman-Roman (Romainville, France),
T. M. Skerry (London, UK)
|
|
Athena Theatre
|
| I002 |
|
Sclerostin is an osteocyte-expressed negative regulator
of bone formation, but not a classical BMP antagonist |
|
C. Löwik (Leiden, Netherlands) |
| I003 |
|
Regulation of bone formation by the FGF2 pathway |
|
M. M. Hurley (Farmington, USA) |
| |
|
|
|
|
10.00 – 11.00
|
Oral Presentations 1
Osteoblasts and Bone Formation Chair: S. Roman-Roman (Romainville, France),
T. M. Skerry (London, UK)
|
|
Athena Theatre
|
| OP001 |
|
Mice lacking Fra-2 are severely osteopenic due to osteoclast
and osteoblast defects
ECTS Young Investigator Award |
|
A. Hoebertz (Vienna, Austria) |
| OP002 |
|
Enhanced trabecular bone mass and architecture in mice
over-expressing ATG1-to-TTG1 mutant histone H4 transgene |
|
B. Frenkel (Los Angeles, USA) |
| OP003 |
|
Identification of novel RUNX2 target genes
ECTS Young Investigator Award |
|
A. Barski (Los Angeles, USA) |
| OP004 |
|
Wnt-signaling regulates human osteoblast differentiation
and mineralization in a steroid-dependent manner
ECTS Young Investigator Award |
|
M. Eijken (Rotterdam, Netherlands) |
| OP005 |
|
Zoledronate up-regulates bone sialoprotein expression
in SAOS-2 cells through RhoA inhibition |
|
M. Chaplet (Liège, Belgium) |
| |
|
|
|
|
11.00 – 12.45 |
|
Coffee and Posters |
|
Hall Agora 2 |
12.00 – 12.45 |
|
Lunch |
|
|
| |
|
|
|
|
12.45 – 14.00
|
Workshop 1
Glucocorticoid-Induced Osteoporosis Chair: N. Franchimont (Liège, Belgium),
L. Euller-Ziegler (Nice, France)
|
|
Athena Theatre
|
| I004 |
|
Epidemiology of glucocorticoid-induced osteoporosis |
|
T. P. Van Staa (Staines, UK) |
| I005 |
|
Mechanisms of osteoblast inhibition by steroids |
|
P. Hulley (Stellenbosch, South Africa) |
| I006 |
|
Prevention and management of glucocorticoid-induced
osteoporosis |
|
D. M. Reid (Aberdeen, UK) |
| |
|
|
|
|
12.45 – 14.00
|
Workshop 2
Biochemical Markers Chair: P. Delmas (Lyon, France),
G. Russell (Oxford, UK)
|
|
Hermès Theatre
|
| I007 |
|
Biology of matrix proteins |
|
D. Heinegard (Lund, Sweden) |
| I008 |
|
New biochemical markers of bone turnover in osteoporosis |
|
P. Garnero (Lyon, France) |
| I009 |
|
Clinical use of biochemical markers |
|
R. Eastell (Sheffield, UK) |
|
|
|
|
|
14.00 – 15.00
|
Symposium 2
Bone Development & Bone Quality Chair: G.
Karsenty (Houston, USA),
M. Kassem (Odense, Denmark)
|
|
Athena Theatre
|
| I010 |
|
Hox genes and limb development |
|
D. Duboule (Geneva, Switzerland) |
| I011 |
|
Why some bones fracture and others don't: a biomechanical
perspective |
|
J. Currey (York, UK) |
| |
|
|
|
|
15.00 – 16.00
|
Oral Presentations 2
Osteoblasts and Bone Formation Chair: G.
Karsenty (Houston, USA),
M. Kassem (Odense, Denmark)
|
|
Athena Theatre
|
| OP006 |
|
Defective bone mineralization and osteopenia in young
adult FGFR3-/- mice |
|
J. Henderson (Montreal, Canada) |
| OP007 |
|
Accelerated bone aging in DNA repair deficient trichothiodystrophy
mice
ECTS Young Investigator Award |
|
K. Diderich (Rotterdam, Netherlands) |
| OP008 |
|
Genetic deficiency in PERK cause severe osteopenia
and neonatal growth retardation |
|
D. Cavener (University Park, USA) |
| OP009 |
|
Prostaglandins-dependent activation of ERK mediates
cell proliferation induced by TGFß in MC3T3-E1 osteoblastic cells |
|
J. Caverzasio (Geneva, Switzerland) |
| OP010 |
|
11ß-hydroxysteroid dehydrogenase expression and glucocorticoid
synthesis is directed by a molecular switch during osteoblast differentiation |
|
M. Eijken (Rotterdam, Netherlands) |
| |
|
|
|
|
16.00 – 16.30 |
Coffee Break |
|
|
| |
|
|
|
|
16.30 – 17.30
|
Oral Presentations 3
Osteoporosis and Fractures Chair: P.
Garnero (Lyon, France),
H. Pols (Rotterdam, Netherlands)
|
|
Athena Theatre
|
| OP011 |
|
Cumulative risks of fracture in patients using oral
glucocorticoids |
|
T. Van Staa (Egham, UK) |
| OP012 |
|
Contrasting effects of teriparatide and alendronate
on bone turnover assessed by bone histomorphometric parameters in
women with osteoporosis |
|
P. Meunier (Lyon, France)
|
| OP013 |
|
Biochemical markers of bone formation are positively
correlated with volumetric BMD following teriparatide therapy |
|
P. Miller (Denver, USA) |
| OP014 |
|
Urine osteocalcin - a novel marker of bone metabolism
and prediction of fractures |
|
K. Ivaska (Turku, Finland) |
| OP015 |
|
Fracture prediction using markers of bone turnover
in the general population: the OPUS study |
|
A. Blumsohn (Sheffield, UK)
|
| |
|
|
|
|
17.30 – 19.30 |
Satellite Symposium
Bone Strength and Fracture Resistance
In Osteoporosis
Supported by The
Alliance for Better Bone Health
Chair: R. Rizzoli (Geneva, Switzerland)
|
|
Hermès Theatre
|
| |
|
Factors influencing bone strength |
|
D. Felsenberg (Berlin, Germany)
|
| |
|
The role of bone quality in fracture risk reduction |
|
R. Lindsay (West Haverstraw, USA)
|
| |
|
Clinical perspectives on differences in bisphosphonate
pharmacology |
|
P. Delmas (Lyon, France)
|
| |
|
Concluding remarks |
|
R. Rizzoli (Geneva, Switzerland) |
